Search results for: Competition
Filter search results
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
…latter. Developing country markets are, however, dominated by generic products and encouraging competition through sharing prices makes sense if capacities are there to use the data to inform procurement decisions…
Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?
17 March 2020
Adrian Towse presented evidence that transparency of process reduced corruption and improved competition. Evidence was, however, against price transparency for on-patent medicines. It will reduce access in low income countries….
OHE Announces New Trustees and Board Chair
10 January 2022
…University. The impact of Professor Kyle’s work extends beyond the academy. Her work informs countries and companies. She is a member of DG Competition’s Economic Advisory Group on Competition Policy….
The Dynamics of Drug Shortages
9 January 2024
…or remained the same. Price erosion does not appear to be driven by competition between manufacturers, since the markets are highly concentrated, but instead from other dynamics that are captured…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
…RD medicines are still characterised by a lack of competition and few treatment alternatives for patients. Access to — and the availability of — effective treatments is crucial for positive…
New OHE Consulting Report Explores the Many Faces of Innovation
19 June 2012
…case studies, and updates the discussion of competition in pharmaceutical R&D. Now available from the OHE website, this report provides a clear explanation of the complex nature of innovation in…
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
…progress stimulates competition and often leads to several products coming to market in a therapy class. This is particularly the case in recent developments in oncology. We propose that a…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…(2018). R&D, Competition and Diffusion of Innovation in EU: the case of Hepatitis C. OHE Research Paper 18/06, London: Office of Health Economics. Available at: https://www.ohe.org/publications/rd-competition-and-diffusion-innovation-eu-case-hepatitis-c Cole, A., Towse,…
Funding Challenges in the Malaysian Health Care System
7 January 2020
Adrian Towse presented at the Monash Malaysia Health Economics Forum 2019 on three related topics: health system financing in Malaysia; pharmaceutical price regulation and competition in Malaysia; and the potential…